What Cibacen Treats: Main Uses and Benefits

---

Cibacen (Benazepril) is commonly used for the long-term management of systemic arterial hypertension (high blood pressure). The medication is used to establish and sustain a stable blood pressure profile, which is considered relevant for overall circulatory health. It is applied in situations where patients experience conditions presenting with systemic imbalance.

Cibacen is applied across domains where additional symptomatic support is needed in the management of conditions marked by increased physiological stress, specifically: essential hypertension, supportive therapy for chronic symptomatic heart failure, and the management of chronic kidney strain in vulnerable patients.

“The therapy is commonly used to help with long-term stability and contributes to easing the overall symptom load associated with chronic cardiovascular stress.”

The medication supports the patient during episodes where symptoms related to systemic imbalance are noticeable. It is considered relevant for managing cardiovascular risk factors, which are often associated with conditions involving heightened physiological stress.

---

Quick Fact: Relief for Systemic Circulatory Stress

Cibacen assists with maintaining functional stability and supports patients during phases when symptoms become more noticeable by addressing the underlying chronic strain.

Regulatory References

1. NIH MedlinePlus overview on Benazepril

Official Eligibility for Cibacen (Benazepril)

Cibacen is an Angiotensin-Converting Enzyme (ACE) inhibitor whose eligibility is strictly defined by regulatory documents based on age, medical history, and specific health conditions. The medicine is contraindicated in several specific patient populations.

Populations for Whom Use is Established

• Adults for the management of hypertension.
• Pediatric patients 6 years of age and older. Use is not established in children younger than 6.

Absolute Contraindications (Must Not Use) Use is strictly prohibited for:

• Women who are pregnant, particularly in the second and third trimesters, due to risk of fetal harm.
• Patients with a history of angioedema (swelling) related or unrelated to ACE inhibitor therapy.
• Individuals with known hypersensitivity to benazepril or any other ACE inhibitor.
• Patients concurrently taking a Neprilysin Inhibitor (e.g., sacubitril) or Aliskiren (if diagnosed with diabetes).

Conditional Use and Restrictions Restrictions apply based on physiological status:

• Severe Renal Impairment (GFR leq 30 mL/min): Requires a lower starting dose for adults and is not recommended for pediatric patients.
• Volume/Salt Depletion: This must be corrected before treatment initiation.
• Lactation: Use is generally regarded as having minimal risk to the infant, though caution is required.

Interactions with other medicines and products

Official regulatory documentation establishes specific prohibitions and restrictions for combining Benazepril (Cibacen) with other substances, primarily concerning pharmacokinetic outcomes and pharmacodynamic additive effects.

Contraindicated Combinations and Timing Rules

Co-administration with Neprilysin Inhibitors (e.g., Sacubitril/Valsartan) is formally contraindicated due to a significantly increased risk of angioedema. A mandatory timing rule requires that Benazepril must not be administered within 36 hours of switching to or from a Neprilysin Inhibitor. Additionally, the combination with Aliskiren is contraindicated for patients with diabetes mellitus or those with documented renal impairment (GFR below 60 mL/min).

Documented Pharmacodynamic Effects

Co-administration with Potassium-sparing Diuretics or Potassium Supplements increases the risk of hyperkalemia (elevated serum potassium levels) due to additive effects. Similarly, the use of Potassium-containing Salt Substitutes may increase this risk. The use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may officially reduce the antihypertensive efficacy of Benazepril and increases the risk of renal function deterioration. Benazepril also reduces the clearance of Lithium, leading to increased serum Lithium concentrations. Furthermore, co-administration with Anti-diabetic agents may increase the risk of hypoglycemia, particularly in patients with diabetes.

Cibacen, which contains the prodrug benazepril, is rapidly metabolized via hepatic esterase cleavage to its active moiety, benazeprilat. Benazeprilat functions as a potent competitive inhibitor of the angiotensin-converting enzyme (ACE), a peptidyl dipeptidase.

ACE is the target enzyme that catalyzes the cleavage of the precursor peptide, angiotensin I, into the potent vasoconstrictor, angiotensin II. By inhibiting this conversion, benazeprilat causes a concentration-dependent reduction in circulating plasma angiotensin II levels. The intracellular cascade triggered by angiotensin II receptor binding is thus attenuated. This molecular inhibition leads to decreased systemic vasopressor activity and a corresponding reduction in the angiotensin II-mediated stimulation of aldosterone secretion by the adrenal cortex. Downstream, reduced aldosterone levels modulate renal distal tubule activity, resulting in decreased sodium and water reabsorption. The combined consequences of systemic vasodilation and decreased circulating blood volume lead to a modulation of overall systemic vascular resistance and circulatory dynamics.

How to Use Cibacen: Official Administration Guidelines

Cibacen (Benazepril hydrochloride) is administered exclusively via the oral route as a tablet. The medicine can be taken with or without food, as the presence of food does not significantly impact absorption. The frequency pattern is typically once daily, although the total dose may be divided into two equal doses (twice daily) to optimize blood pressure control.

---

Standard Dosing Regimens

Dosing is personalized and generally follows a low-dose initiation and gradual titration pattern:

• Hypertension (Adults): Therapy usually starts at 10 mg once daily for patients not receiving a diuretic, or 5 mg once daily if a diuretic is already being used. The dose is typically adjusted every one to two weeks, with the usual maintenance range being 20 mg to 40 mg per day.
• Heart Failure (Adults): Initial dosing is typically lower at 2.5 mg once daily, and the dose is slowly titrated up to a maximum of 20 mg daily based on response.

---

Population-Specific Use and Preparation

Specific adjustments are mandated for certain patient populations. For adults with severe renal impairment (kidney disease), the initial daily dose is reduced to 5 mg. In older adults (geriatric patients), a lower starting dose of 5 mg once daily may be recommended for hypertension. For pediatric patients (age 6 and older), the starting dose is weight-based at 0.2 mg/kg once daily, up to a maximum of 40 mg per day. For these patients, or those unable to swallow tablets, an oral suspension may be prepared from the 20 mg tablets following specific instructions provided in the product labeling.

If a dose is missed, it should be taken as soon as possible, unless it is close to the time for the next dose, in which case the missed dose should be skipped.

Research Evidence / Overview of Studies for Cibacen

Evidence for use in Systemic Arterial Hypertension (High Blood Pressure)

This section summarizes the types of high-quality studies, including large-scale Randomized Controlled Trials (RCTs), that research examined Benazepril in studies related to blood pressure levels and long-term cardiovascular events in adults with high blood pressure.

Studies monitored change in Systolic and Diastolic Blood Pressure (SBP/DBP), which are outcomes monitoring physiological strain or stress within the circulatory system. Studies monitored the rate of serious, long-term cardiovascular events, such as nonfatal stroke or heart attack. Research highlights changes measured during the study period, including measured reductions in blood pressure over defined time intervals.

What remains uncertain is that the most extensive data on long-term cardiovascular outcomes often comes from studies where Benazepril was evaluated in combination therapy, not alone. Therefore, specific evidence on its long-term effects as a single agent may be limited. Regulatory documentation notes that the blood pressure response observed in some studies was less pronounced in Black patients when Benazepril was used as monotherapy.

Evidence for use in Chronic Kidney Strain (non-diabetic Proteinuria)

This section describes the specialized research, including double-blind renal outcome trials, that focused on populations with non-diabetic chronic kidney issues and what endpoints were measured over several years.

Benazepril was evaluated in specific long-term trials focused on adults who had advanced chronic kidney strain. Researchers monitored for composite endpoints, including the doubling of serum creatinine levels and the onset of end-stage kidney disease. Findings describe patterns observed in these studies. An analysis of patients with more advanced renal insufficiency reported patterns in the rate of decline in renal function and also described observed changes in the level of protein being excreted in the urine (proteinuria) when compared to a placebo.

Evidence in Special Populations

Research has explored Benazepril's use in specific populations, notably in children and adolescents aged 6 to 16 years with hypertension. These pediatric studies were primarily short-term, placebo-controlled withdrawal trials that measured changes in trough blood pressure. For older adults and those with complex coexisting conditions, these groups were evaluated in the large-scale adult hypertension trials, and specific subgroup findings are uncertain but generally followed overall trial patterns.

What is Still Uncertain in the Research Record

Several areas in the research record are still characterized by uncertainty. For instance, the long-term effects for the pediatric population are not fully established because the trials were of short duration. Additionally, data for certain groups remain insufficient, such as children under 6 years of age, for whom research is limited.

Common questions about Cibacen (FAQ)

Q: How long does it typically take to feel any effect from Cibacen?

A: The official product information indicates that the full therapeutic effect of Cibacen, which is to lower blood pressure, may take some time to become fully established. Regulatory information indicates that the full therapeutic benefit may take a few weeks to be observed.

Q: Is it true that Cibacen is a 'water pill'?

A: Cibacen is classified as an Angiotensin-Converting Enzyme (ACE) inhibitor. Official classifications state that this medicine is not a diuretic, which is the class of drugs commonly referred to as 'water pills.'

Q: Are there any common foods or drinks to avoid while taking Cibacen?

A: Regulatory documents caution against combining this medicine with potassium supplements or salt substitutes that contain potassium. Official warnings mention that moderately high or high dietary intake of potassium may need to be avoided.

Q: Does Cibacen affect blood sugar levels?

A: Official interaction warnings describe a potential for increased risk of low blood sugar, known as hypoglycemia, when Cibacen is used at the same time as anti-diabetic agents.

Q: Are there different brand names for the medicine in Cibacen?

A: Yes. The active ingredient in Cibacen is Benazepril hydrochloride. This same substance is also marketed under another brand name, which is Lotensin.

Q: Does alcohol change how Cibacen works in the body?

A: Regulatory documents note that alcohol and Cibacen may have combined effects that further reduce blood pressure. This can potentially increase the occurrence of symptoms such as dizziness or lightheadedness.

Q: Can Cibacen cause a dry cough?

A: Yes, a dry cough is described in official safety information as a common side effect of Cibacen. This type of non-productive cough is a recognized characteristic associated with the entire class of ACE inhibitor medicines.

Q: Is Cibacen known to cause swelling in the hands or feet?

A: Official adverse reaction reports indicate that swelling of the ankles, feet, or lower legs, sometimes called peripheral edema, has been reported as a less common side effect of the medicine.

Q: Can I take Cibacen if I have a history of liver issues?

A: Regulatory warnings note that hepatic toxicity (liver damage) has been associated with this medicine. Therefore, the product label advises healthcare providers to monitor for signs of liver failure or jaundice (yellowing of the skin or eyes).

Q: What kind of blood tests might a doctor ask for while I'm on Cibacen?

A: Due to the physiological actions of Cibacen, official safety documentation emphasizes the need for regular monitoring. Healthcare providers may frequently monitor blood tests, specifically those related to serum potassium levels and overall renal function (kidney function).

Q: Does Cibacen interact with herbal supplements?

A: While specific herbal interactions are often not detailed individually, official documentation advises that healthcare providers be informed about all non-prescription products, including herbal remedies and supplements.

Q: How is Cibacen different from an ARB medicine?

A: Cibacen is an ACE inhibitor, which functions by blocking the enzyme that produces the substance called Angiotensin II. In contrast, an ARB (Angiotensin II Receptor Blocker) medicine works by blocking the Angiotensin II substance from binding to receptors in the body.

Q: What are the official guidelines regarding using Cibacen before surgery?

A: Official regulatory guidelines state that healthcare professionals in charge should be informed if a patient is taking this medicine before any type of surgery. This includes emergency treatment or routine dental surgery.

Q: Does Cibacen cause sensitivity to the sun?

A: Official postmarketing safety reports have included rare occurrences of photosensitivity, which is an increased sensitivity to sunlight. This means that exposure to the sun may cause an adverse reaction for some patients.

Q: Is there any research on the use of Cibacen in people with diabetes?

A: Research and official indications show that Cibacen can be used to treat high blood pressure. Additionally, it has a role in managing kidney disease, specifically diabetic kidney disease (nephropathy), in certain populations.

Q: Can Cibacen affect my ability to drive or operate machinery?

A: Official safety warnings note that Cibacen may cause dizziness. Due to the potential for dizziness, official warnings indicate that activities like driving or operating heavy machinery may need to be avoided until the medicine's effect on the individual is understood.

Q: Can Cibacen affect a person's mood?

A: Less common adverse reactions reported in official documents include central nervous system effects such as insomnia (difficulty sleeping) and feelings of anxiety.

Q: Can Cibacen be crushed or split?

A: Regulatory instructions for proper use indicate the tablet is typically intended to be swallowed whole. It should not be broken, crushed, or chewed, unless it is being prepared for a liquid suspension under specific guidance from a healthcare provider.

Q: How is Cibacen eliminated from the body?

A: The active form of the medicine, benazeprilat, is mainly removed from the body through the biliary (or bile) route, accounting for approximately 85% of elimination. The remaining amount is passed out through the urine.

Q: Are there specific vitamins that interact with Cibacen?

A: Official patient information advises that healthcare providers be informed about all supplements, including vitamins, as these products may affect the way the medicine works.

Q: Can Cibacen affect sexual function?

A: Official postmarketing reports include effects on sexual function. Reported side effects include decreased interest in sexual intercourse and erectile dysfunction (the inability to have or maintain an erection).

Q: How long does Cibacen stay in your system after stopping it?

A: Official pharmacokinetic studies indicate the elimination half-life of the active substance, benazeprilat, is approximately 10 to 11 hours. This half-life is the time it takes for the concentration of the medicine in the body to be reduced by half.

Q: What is the typical timeframe for a follow-up appointment after starting Cibacen?

A: Authoritative guidelines for the management of blood pressure suggest that a follow-up appointment is typically recommended within about one month after starting a new blood pressure medicine. This appointment is used to assess how well the medicine is working and to monitor for any side effects.

Storage Requirements for Cibacen Tablets

Cibacen (benazepril hydrochloride) tablets must be maintained under specific conditions as defined in regulatory labeling. The medicine must be stored at controlled room temperature, which is 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. It is essential to keep the tablets from freezing, and storage areas must protect the product from direct light and excess moisture. The medication must be kept in the container it came in, and the container must be tightly closed.

Child-Safety and Disposal

To ensure safety, the product must be stored out of the sight and reach of children, and safety caps must always be locked. For disposal, consumers are instructed not to keep outdated or unneeded medicine. Official guidance recommends asking a healthcare professional or pharmacist for instructions on discarding any unused product. The tablets must not be flushed down the toilet or poured down a sink.